Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Arcturus Therapeutics Holdings Inc. director Moncef Slaoui received a grant of stock options as part of annual board compensation. The award covers 15,000 options for Common Stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds 15,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Slaoui Moncef
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 15,000 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 15,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 15,000 options
Exercise price: $7.30 per share
Underlying shares: 15,000 shares
+2 more
5 metrics
Options granted
15,000 options
Annual 2026 board grant to director
Exercise price
$7.30 per share
Stock option exercise price
Underlying shares
15,000 shares
Common Stock underlying granted options
Expiration date
June 5, 2036
Option term end date
Total derivative holdings
15,000 options
Total options held after grant
Key Terms
Stock option (right to buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock option (right to buy) financial
"security_title: "Stock option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "7.3000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-05T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"Shares underlying the option vest monthly over a one year period"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Board of Directors financial
"2026 annual grant to the Reporting Person as a member of the Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
What did ARCT director Moncef Slaoui report in this Form 4 filing?
Moncef Slaoui reported receiving a grant of 15,000 stock options. These options relate to Arcturus Therapeutics Common Stock and were awarded as his 2026 annual grant for service on the Board of Directors.
What are the key terms of Moncef Slaoui’s new ARCT stock options?
The grant consists of 15,000 stock options with an exercise price of $7.30 per share. The options are scheduled to expire on June 5, 2036, giving the director a long exercise window tied to company service.
How do the ARCT options granted to Moncef Slaoui vest over time?
The 15,000 options vest in monthly installments over one year from the grant date. This creates a steady vesting schedule aligned with ongoing Board service rather than a single cliff-vesting event.
How many derivative securities does Moncef Slaoui hold after this ARCT grant?
After the 15,000-option grant, Slaoui holds 15,000 derivative securities directly. These represent rights to acquire an equal number of Arcturus Therapeutics Common Stock shares if he chooses to exercise the options in the future.